Himension Capital Singapore PTE. LTD. Makes New Investment in IQVIA Holdings Inc. (NYSE:IQV)

Himension Capital Singapore PTE. LTD. acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 26,066 shares of the medical research company’s stock, valued at approximately $5,122,000. IQVIA makes up 0.4% of Himension Capital Singapore PTE. LTD.’s portfolio, making the stock its 27th largest holding.

A number of other institutional investors and hedge funds have also modified their holdings of IQV. Synergy Asset Management LLC bought a new stake in shares of IQVIA during the fourth quarter valued at approximately $33,000. Lee Danner & Bass Inc. bought a new stake in shares of IQVIA during the fourth quarter valued at approximately $44,000. Zions Bancorporation N.A. increased its stake in shares of IQVIA by 55.2% in the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock valued at $47,000 after buying an additional 85 shares during the period. Versant Capital Management Inc increased its position in IQVIA by 46.0% in the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock worth $58,000 after purchasing an additional 93 shares during the period. Finally, SBI Securities Co. Ltd. acquired a new position in IQVIA in the fourth quarter valued at approximately $60,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages recently commented on IQV. Bank of America dropped their price objective on IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Morgan Stanley boosted their price target on IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 11th. Royal Bank of Canada reiterated an “outperform” rating and issued a $270.00 target price on shares of IQVIA in a research note on Monday, February 10th. BTIG Research cut shares of IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. Finally, Robert W. Baird dropped their price target on IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a report on Tuesday, January 21st. Five analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Price Performance

NYSE IQV opened at $154.63 on Friday. The company’s 50 day moving average is $189.67 and its two-hundred day moving average is $203.82. IQVIA Holdings Inc. has a 12 month low of $154.35 and a 12 month high of $252.88. The stock has a market cap of $27.26 billion, a price-to-earnings ratio of 20.62, a PEG ratio of 1.99 and a beta of 1.46. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, research analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.